Physician profile
Jeffrey Gaitz
NPI 1922044510
$11,220.18
in general payments reported to CMS, 2019-2025
44 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,382 · 2020: $1,138 · 2021: $2,038 · 2022: $1,248 · 2023: $1,562 · 2024: $1,419 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,314 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,314.37 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $1,058.47 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $766.92 | 2019-2025 | |
| Abbvie INC. | $747.64 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $700.73 | 2019-2025 | Nuplazid |
| Ucb, INC. | $629.67 | 2019-2023 | Briviact, Nayzilam |
| Amneal Pharmaceuticals LLC | $610.82 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Teva Pharmaceuticals USA, INC. | $596.67 | 2019-2025 | Ajovy, Austedo Xr |
| Genentech USA, INC. | $555.95 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Activase |
| Otsuka America Pharmaceutical, INC. | $537.76 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $516.20 | 2020-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $506.09 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $372.15 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Eisai INC. | $289.02 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $264.99 | 2019-2025 | Qelbree |
| Emd Serono, INC. | $264.81 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gaitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.